- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07695493
Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis (PREVI)
An Open-label Randomized Trial Evaluating the Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The HIV/AIDS epidemic remains uncontrolled in France, with approximately 5,000 to 6,000 new cases reported each year. Since January 2016, HIV pre-exposure prophylaxis (PrEP)-which involves taking a single oral tablet containing two antiretroviral drugs-has been available in France. The effectiveness of this PrEP has been demonstrated, with a relative reduction in HIV incidence of nearly 97% when PrEP is taken correctly.
However, only nearly 50,000 people are using PrEP in France in 2024, which is far short of the targets needed to control the epidemic. Indeed, the population of men who have sex with men (MSM) at risk of HIV infection is estimated at over 200,000, and the number of heterosexuals on PrEP is negligible, even though 40% of new HIV diagnoses involve heterosexuals from countries with high prevalence (Sub-Saharan Africa).
Furthermore, these 50,000 people on PrEP represent only 64% of the >120,000 people who have started PrEP since 2016, indicating that many have discontinued this prophylaxis over time. One of the challenges in implementing PrEP stems from the small number of trained hospital and primary care physicians and their limited time availability to provide a PrEP care.
Since 2022, PrEP training programs in medical settings, involving nurses, have been implemented to train them to monitore people on PrEP. This involvement of nurses would help increase the availability of PrEP, free up doctors' time for complex cases, and enhance the value of nursing work.
However, there has been no evaluation of this care provided by nurses to people on PrEP in terms of quality, acceptability, satisfaction among people on PrEP, nurses, and doctors, or its cost-effectiveness.
The aim of our study is therefore to assess whether the care provided to subjects on PrEP by these nurses is as good, well-accepted, and satisfactory for subjects and caregivers as it would be if the care were provided solely by physicians.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jérôme Lambert, MD PhD
- Número de telefone: +33 0142499742
- E-mail: jerome.lambert@u-paris.fr
Estude backup de contato
- Nome: Bénédicte Loze, Nurse
- Número de telefone: +33 01.42.49.48.52
- E-mail: benedicte.loze@aphp.fr
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Male sex assigned at birth, aged ≥ 18 years
- Individual at risk of HIV infection
- Currently receiving PrEP care and willing to continue follow-up in a hospital setting
- Receiving care at a hospital setting by a physician and not objecting to follow-up by a nurse
- Having received complete information about the study and having provided a free written informed consent
- Affiliated with a social security system (beneficiary or entitled individual) or covered by State Medical Aid (AME).
Exclusion Criteria:
- Individual with confirmed HIV infection
- Currently receiving nurse care in a hospital setting
- Having renal impairment (creatinine clearance < 60 mL/min)
- Unable to provide informed consent
- Not affiliated with a social security system or not covered by State Medical Aid (AME)
- Under legal guardianship or curatorship
- Deprived of liberty by judicial or administrative decision, or individuals receiving psychiatric care under Article L1121-6 of the French Public Health Code
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Follow-up visits for PrEP prescription conducted by a physician.
|
Monitoring of PrEP by physicians
|
|
Experimental: Follow-up visits for PrEP prescription conducted by a nurse under the same conditions.
|
Monitoring of PrEP by nurses
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Compliance to PrEP
Prazo: Up to 12 months
|
Compliance to PrEP is defined by a composite criterion comprising:
|
Up to 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Occurrence of sexually transmitted infection (STI)
Prazo: At baseline
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At baseline
|
|
Occurrence of sexually transmitted infection (STI)
Prazo: At 6 months
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At 6 months
|
|
Occurrence of sexually transmitted infection (STI)
Prazo: At 12 months
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At 12 months
|
|
Tolerability of PrEP
Prazo: At baseline
|
Plasma creatine level
|
At baseline
|
|
Tolerability of PrEP
Prazo: At 6 months
|
Plasma creatine level
|
At 6 months
|
|
Tolerability of PrEP
Prazo: At 12 months
|
Plasma creatine level
|
At 12 months
|
|
PrEP adherence
Prazo: At 12 months
|
Number of patient visits completed during the year and Tenofovir diphosphate concentrations
|
At 12 months
|
|
Treatment acceptability among participants
Prazo: Up to 12 months
|
Number of participants who discontinued follow-up and reasons for discontinuation
|
Up to 12 months
|
|
Incidence of HIV infection
Prazo: Up to 12 months
|
HIV infection during follow up (positive serology or HIV RNA)
|
Up to 12 months
|
|
Cost of care
Prazo: Up to 12 months
|
From the perspectives of the healthcare system, patients, and health insurance : Incremental or decremental cost-effectiveness ratio (Cost per patient, Time spent in consultations, Number of prescribed labs and tests, and Number and duration of any hospitalizations…)
|
Up to 12 months
|
|
Patient and caregiver satisfaction
Prazo: At 12 months
|
Focus groups
|
At 12 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções transmitidas pelo sangue
- Doenças urogenitais
- Doenças Genitais
- Doenças do sistema imunológico
- Infecções
- Infecções por vírus de RNA
- Doenças Virais
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Síndromes de Deficiência Imunológica
- Infecções por HIV
Outros números de identificação do estudo
- APHP230860
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .